University of Columbia and Illumina locked in DNA patent battle

The University of Columbia has hit Illumina with a patent infringement suit relating to next-generation DNA sequencing, just days after the pharmaceutical company had one of the university’s patents invalidated at the US Patent and Trial Appeal Board (PTAB).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Genetics

Charpentier CRISPR patent gets good news from Japan

14 December 2023 Novelty and inventive step of patent owned by ERS Genomics and Emmanuelle Charpentier withstand challenge at Japan Patent Office | Invalidity proceedings also rejected by JPO in 2021.

Genetics

Will de-extinct animals be patent eligible in the US?

5 January 2023 Science fiction is becoming science fact but the Alice/Mayo framework throws up some interesting challenges to bringing life back from the dead, explains Brian Hausman of Baker Botts.

Genetics

Gene-editing bill: encouraging innovation or adding complexity?

26 May 2022 UK legislation to streamline gene-editing technology research is promising for innovation, but presents potential complications for IP, finds Sarah Speight.

More features

Senior four-partner team leaves A&O Shearman

Final call: Who are the world’s best in-house counsel?

ITC to probe Oura Ring after Samsung retaliates, seeking import ban

Speciality pharma firm stumbles on bid to enforce Belbuca ruling

Italian medtech startup beats larger US rival in UPC dispute

Senior USPTO solicitor steps into private practice

Goodwin targets transatlantic patent work with London hire

Bayer secures key Denmark ruling as Xarelto faces expiry pressure

University of Columbia and Illumina locked in DNA patent battle

More on this story

Editor's picks

Editor's picks

More features